ArticleMolecular and clinical oncology2025
POSTN is exclusively activated in cancer-associated fibroblasts and leads to unfavorable prognosis of patients with gastric cancer.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- POSTN⁺ CAF-SPP1⁺ macrophage crosstalk is associated with immune exclusion and poor prognosis in lung adenocarcinoma.Journal of translational medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance significantly impairs the prognosis of patients with gastric cancer (GC). As a key player in the acquisition of drug resistance, understanding the detailed evolution of the GC tumor microenvironment (TME) is crucial for improving therapeutic effectiveness. The clinical significance of markers related to cancer-associated fibroblast (CAF) proliferation and extracellular matrix remodeling were analyzed using public databases and immunohistochemistry staining on an in-house cohort of patients with GC. Combining this with single-cell RNA sequencing data revealed the expression patterns of all candidate markers, highlighting POSTN due to its pronounced upregulation in CAFs and its strong correlation with poor prognosis in patients with GC. Mechanistically, POSTN is directly regulated by the YAP1/TEAD1 co-transcription factor and is demonstrated to play significant roles in fibroblast proliferation and migration processes. The present study underscores POSTN as a promising marker for predicting GC prognosis and a powerful regulator that can augment the tumorigenic phenotypes of CAFs, providing a potential target to mitigate CAF-originated drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.